Comparing of Unum Therapeutics Inc. (UMRX) and Krystal Biotech Inc. (NASDAQ:KRYS)

Unum Therapeutics Inc. (NASDAQ:UMRX) and Krystal Biotech Inc. (NASDAQ:KRYS) compete with each other in the Biotechnology sector. We will analyze and compare their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Unum Therapeutics Inc. 10.57M 6.93 39.49M -1.60 0.00
Krystal Biotech Inc. N/A 0.00 12.85M -1.04 0.00

Table 1 shows the top-line revenue, earnings per share and valuation for Unum Therapeutics Inc. and Krystal Biotech Inc.

Profitability

Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Unum Therapeutics Inc. -373.60% -96.5% -42.3%
Krystal Biotech Inc. 0.00% -16% -15.5%

Liquidity

Unum Therapeutics Inc. has a Current Ratio of 3.2 and a Quick Ratio of 3.2. Competitively, Krystal Biotech Inc.’s Current Ratio is 33.3 and has 33.3 Quick Ratio. Krystal Biotech Inc.’s better ability to pay short and long-term obligations than Unum Therapeutics Inc.

Insider and Institutional Ownership

Unum Therapeutics Inc. and Krystal Biotech Inc. has shares held by institutional investors as follows: 47.9% and 43.4%. Insiders held 39.76% of Unum Therapeutics Inc. shares. Competitively, 32.99% are Krystal Biotech Inc.’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Unum Therapeutics Inc. -1.51% -15.76% -24.36% -54.66% -69.13% -25.91%
Krystal Biotech Inc. 8.63% 14.16% 56.25% 56.67% 246.53% 68.43%

For the past year Unum Therapeutics Inc. had bearish trend while Krystal Biotech Inc. had bullish trend.

Summary

Krystal Biotech Inc. beats on 7 of the 9 factors Unum Therapeutics Inc.

Unum Therapeutics Inc., a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma. The company's product portfolio also includes ACTR707 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r B cell non-Hodgkin lymphoma; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; and ACTR707 used in combination with trastuzumab, which is in late preclinical development phase for treating HER2+ solid tumor cancers. It has strategic collaboration with Seattle Genetics, Inc. to identify, research, develop, and commercialize antibody-coupled T cell receptor therapies. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases. The companyÂ’s lead product candidate includes KB103, which is in preclinical studies to treat dystrophic epidermolysis bullosa, a genetic disease. It also develops KB104 that is in preclinical studies to treat Netherton syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is based in Pittsburgh, Pennsylvania.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.